XEN Glaucoma Implant for the Management of Operated Uncontrolled Glaucoma: Results and Complications during a Long-Term Follow-Up

This study aimed to analyze the surgical and refractive outcomes of XEN glaucoma implant (Allergan, an Abbvie company, Irvine, CA, USA), a minimally invasive surgical device for the treatment of operated uncontrolled glaucoma. Eyes that received XEN Gel Stent placement from December 2014 to October...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Katarzyna Lewczuk, Joanna Konopińska, Joanna Jabłońska, Jacek Rudowicz, Patrycja Laszewicz, Zofia Mariak, Marek Rękas
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2021-01-01
Colecção:	Journal of Ophthalmology
Acesso em linha:	http://dx.doi.org/10.1155/2021/2321922
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!